Provider review
Zeuss carries a February 2026 federal warning letter for false and misleading claims, addressed to the company at the email address on this very site. It sells GHK-Cu only inside a three-ingredient hair formula, so it publishes no copper-peptide price at all.
Disclosure score, 6 checks
Best fora reader who wants to see what a lettered telehealth seller looks like before buying from one
Zeuss does not publish a price today.
Zeuss also sells 1 compound this site boards without publishing a price for it: GHK-Cu.
What Zeuss states on its own site about leaving, getting money back, and what delivery costs. Read on September 2026.
Whether Zeuss charges to belong, on top of what it charges for the medication. Read on September 2026.
Whether Zeuss identifies the clinician or medical practice behind the prescription, or describes them only as a group. Read on September 2026.
Zeuss is not a paid partner; this link may earn a commission if that changes. Full disclosure.
A warning letter issued in February 2026 names Zeuss LLC, trading as Zeuss, for false and misleading claims and misbranding in a telehealth context.
This is not a coincidence of names. The letter's recipient block carries the support address at this domain, and its opening line says the agency reviewed the content at this site's own web address.
Zeuss LLC appears once in that federal table, and no other seller compared here matches it.
Both hair formulas Zeuss sells put a copper peptide alongside two other actives, with each ingredient's strength printed.
So there is no copper-peptide price to compare. Every figure Zeuss publishes buys a three-drug formula, and treating that number as a GHK-Cu price would say the money buys something it does not.
Zeuss does dispense the compound. What it never publishes is a price for the compound on its own.
Zeuss states that compounded medications have not been approved by the FDA, and that the agency does not verify the safety, effectiveness or quality of compounded drugs.
It names Zeuss LLC as the operating company in its own terms, repeatedly, so the entity can be looked up.
It offers a full refund if a physician cannot prescribe treatment, and it prints the milligram strength of every ingredient in its formulas.
Zeuss publishes no list of the states it serves.
It names no dispensing pharmacy, and no certificate of analysis is reachable from the site.
A warning letter is a finding about what a company said, not about the drug in the box. It is still on the public record, and worth knowing before you buy.
Zeuss received an FDA warning letter issued February 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
Auren Rx names both its prescribing group, Wasef Health, and its dispensing pharmacy, VialsRX in Houston, with street addresses and phone numbers, and lets a subscriber pause an auto-refill plan on NAD+, sermorelin, glutathione or GHK-Cu instead of forcing a full cancellation.
Auren Rx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Auren RxFalse and misleading claims and misbranding, in a telehealth context, issued in February 2026. It concerns what the company published, not a defect found in a specific medicine.
Yes. The letter's recipient block carries this site's own support email address, and its opening line names this site's web address as the content the agency reviewed.
Because every figure Zeuss publishes buys a formula containing a copper peptide plus two other actives. Calling that a GHK-Cu price would misdescribe what the money buys.
It does not say that. This letter is about claims and labeling. It is public, and worth knowing, but it is not a finding about what arrives in the box.
Zeuss is not a paid partner; this link may earn a commission if that changes. Full disclosure.